Alcon’s Net Sales Grow 8 Percent in Q4-2017, 4 Percent for Full Year

February 2, 2018: By Jon Swedien

Alcon’s net sales for Q4-2017 were $1.56 billion (8 percent, 6 percent cc), parent company Novartis reported Jan. 24.

Alcon’s net sales for the full year were $6 billion (4 percent, 4 percent cc), Novartis reported.

Annual surgical sales were $3.7 billion, up 5 percent (cc), Novartis said in its 2017 annual report. The growth was mainly due to strong performance of products in the vitreoretinal portfolio and growth in cataract disposable surgical supplies, Novartis said.

Vision Care sales were $2.4 billion (3 percent, cc), Novartis said.

CEO Vasant Narasimhan said Novartis is still considering a possible spinoff of Alcon in the first half of 2019. Narasimhan took over for former CEO Joseph Jimenez on Feb. 1.

“We are making progress toward the capital market exit with dedicated teams working toward that,” Narasimhan said in a Jan. 24 earnings call. “But there is no change on the timing of a potential action; we continue to guide toward the potential action in the first half of 2019.”

Novartis posted $12.9 billion (5 percent, 2 percent cc) in Q4-2017. The company’s net sales for the full year were $49 billion (1 percent, 2 percent cc).

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023